Therapeutic Antibodies: Bench to Market

Webinar Series of the Chinese Antibody Society

Upcoming Webinar

Register today to reserve your seat


Dr. Cheng Liu is the Founder, President and CEO of Eureka Therapeutics. Prior to founding Eureka, he was a Principal Scientist in antibody drug discovery at Chiron (now Novartis). With over 20 years of experience in the field, Dr. Liu holds more than 500 patents and published patent applications of which over 100 patents have issued worldwide and has authored numerous peer-reviewed papers on cancer immunotherapy. Dr. Liu is the inventor of multiple first-in-class, clinical-stage cancer drugs against various tumor targets, including drugs targeting CSF1 for the treatment of bone metastasis, BCMA for multiple myeloma, and AFP and GPC3 for liver cancer. In 2007, he was awarded Special U.S. Congressional Recognition for his contributions to improving human health. Dr. Liu is the editor of the book “Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development”. Dr. Liu received his B.S. in Cell Biology and Genetics from Peking University and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.

Sign in to Register

Recent Webinars

Sign in to view recordings

PROTABs A Tool For Leveraging E3 Ubiquitin ligases As Cell Surface Protein Degraders


Dr. Hadir Marei

Protein ubiquitylation is central to proper cellular functioning by providing a fine-tuning mechanism that controls protein activity, subcellular localization and turnover. Canonical protein ubiquitylation involves a three-step enzymatic cascade with substrate specificity dictated by E3 ubiquitin ligases that transfer ubiquitin to a target protein. As such, advances allowing the regulation …

CMC Regulatory Considerations for Antibody-Drug Conjugates


Dr. Li Wan

Antibody-drug conjugates (ADCs) are the latest effective treatment for malignant tumors, following chemotherapy, targeted therapy, and immunotherapy. ADCs combine both the high targeting specificity of antibodies and the potent cytotoxicity of chemotherapy drugs, enabling selective delivery of highly toxic chemotherapy drugs to tumor cells using the high specificity of antibodies, …

Challenges and opportunities in the biopharmaceutical formulation development


Dr. Frank (Yunsong) Li

Biopharmaceutical molecules such as monoclonal antibodies (mAbs) have complex molecular structure and degradation mechanism. It is important in the early stage of the CMC development to address those degradations by thorough formulation development with advanced analytical tools. This presentation will introduce 1. Key aspects of the mAbs degradation pathway in …

Progress and Breakthroughs of TIL therapy in Solid Tumors


Dr. Yarong Liu

This lecture will revolve around four key points: the unique advantages of TIL in the treatment of solid tumors compared with other cell therapies; clinical progress of TIL therapy in treatment of different types of solid tumors in recent years; Grit Bio's efforts on promoting the clinical translation of TIL …